StockNews.AI
ALNY
StockNews.AI
144 days

FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B

1. Alnylam's Qfitlia received FDA approval as a novel RNAi therapeutic. 2. It's the first drug to lower antithrombin, addressing bleeding disorders.

FDA Approval
+0.58%Current Return
VS
+0.63%S&P 500
$268.4603/28 05:21 PM EDTEvent Start
$270.0203/31 05:43 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Very Bullish?

FDA approval of Qfitlia could significantly enhance ALNY's revenue potential, akin to approvals of prior RNAi therapeutics like Onpattro.

How important is it?

The unique mechanism of Qfitlia positions ALNY for leadership in RNAi therapy, suggesting high investor interest and market confidence.

Why Long Term?

Successful market introduction and adoption of Qfitlia could drive sustained growth, similar to previous product launches that expanded market share over months to years.

Related Companies

VRTXSGENBMRN
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration's (FDA) approval of Qfitlia™ (fitusiran), the sixth Alnylam-discovered RNAi therapeutic approved in the U.S., and the first and only therapeutic to lower antithrombin (AT), a protein that inhibits blood clotting, with the goal of promoting thrombin generation to rebalance hemostasis and prevent bleeds.

Related News